Sun Pharma Advanced Research Company Limited has formally notified stock exchanges about the resignation of a senior management personnel. The company informed the National Stock Exchange of India and BSE Limited on April 03, 2026, regarding the departure of Dr. Shravanti Bhowmik from her executive position.

Resignation Details

Dr. Shravanti Bhowmik, who served as Head of Operations Management and was a member of the Senior Management Team, resigned from her position effective from the close of business hours on March 31, 2026. The resignation was communicated to the company through a formal letter dated March 26, 2026.

Regulatory Compliance

The intimation was made under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Kajal Damania signed the formal communication to both stock exchanges, ensuring compliance with mandatory disclosure requirements for senior management changes.

Transition to Group Company

In her resignation letter, Dr. Bhowmik indicated that her departure stems from a transition to a new opportunity within the group company. She expressed her intention to continue professional growth while contributing to the broader organizational goals. The executive acknowledged the support and guidance received during her tenure, describing her experience as enriching while working with the dedicated team.

Professional Acknowledgment

Dr. Bhowmik's resignation letter reflected appreciation for the opportunities and trust extended to her during her role as VP - Operations Management. She expressed commitment to staying connected and continuing to contribute to the overall success of the group, indicating a positive transition within the organizational structure.

Sun pharma advanced research co has issued a formal clarification to BSE Limited following an inquiry about increased trading volume in its shares on March 27, 2026.

Regulatory Compliance Confirmation

The pharmaceutical research company confirmed its adherence to all applicable disclosure requirements under SEBI regulations. The clarification was submitted in response to BSE's communication reference L/SURV/ONL/PV/SG/ 2025-2026 / 1006.

SEBI Regulation 30 Compliance

The company specifically addressed compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates timely disclosure of material events and information that could impact investor decisions.

Kajal Damania, Company Secretary and Compliance Officer, digitally signed the communication confirming that:

• All required disclosures under Regulation 30 have been made to exchanges
• The company is not aware of any undisclosed information qualifying for disclosure
• The organization remains committed to adequate and timely disclosures

Market Surveillance Response

The clarification represents a standard response to stock exchange surveillance mechanisms designed to monitor unusual trading activity. BSE's inquiry followed observed volume increases, prompting the regulatory compliance confirmation from the pharmaceutical research company.

The company requested BSE to take the clarification on record, maintaining transparency in its communication with market regulators and stakeholders.